{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:09:55Z","timestamp":1778425795182,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42471-6","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T19:03:58Z","timestamp":1774206238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas"],"prefix":"10.1038","volume":"16","author":[{"given":"Aur\u00e9lie","family":"Dupuy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Beldi-Ferchiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Poullot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Tari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Naudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Fataccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barkha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"42471_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"42471_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo, E. et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140, 1229\u20131253 (2022).","journal-title":"Blood"},{"key":"42471_CR3","doi-asserted-by":"publisher","unstructured":"De Leval, L. L., Gaulard, P. & Dogan, A. A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas. Blood Journal blood. 2023021786 https:\/\/doi.org\/10.1182\/blood.2023021786 (2024).","DOI":"10.1182\/blood.2023021786"},{"key":"42471_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","volume":"12","author":"S Ayyappan","year":"2019","unstructured":"Ayyappan, S. & Maddocks, K. Novel and emerging therapies for B cell lymphoma. J. Hematol. Oncol. 12, 82 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"42471_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore, D. et al. Peripheral T cell lymphomas: from the bench to the clinic. Nat. Rev. Cancer. 20, 323\u2013342 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"42471_CR6","first-page":"2332","volume":"14","author":"D Sibon","year":"2022","unstructured":"Sibon, D., Peripheral, T-C. & Lymphomas Therapeutic Approaches Cancers 14, 2332 (2022).","journal-title":"Therapeutic Approaches Cancers"},{"key":"42471_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2217\/imt-2018-0002","volume":"10","author":"B Wahid","year":"2018","unstructured":"Wahid, B. et al. An overview of cancer immunotherapeutic strategies. Immunotherapy 10, 999\u20131010 (2018).","journal-title":"Immunotherapy"},{"key":"42471_CR8","doi-asserted-by":"publisher","first-page":"961805","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu, C., Yang, M., Zhang, D., Chen, M. & Zhu, D. Clinical cancer immunotherapy: Current progress and prospects. Front. Immunol. 13, 961805 (2022).","journal-title":"Front. Immunol."},{"key":"42471_CR9","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.3390\/ijms23105686","volume":"23","author":"HG Shin","year":"2022","unstructured":"Shin, H. G., Yang, H. R., Yoon, A. & Lee, S. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. IJMS 23, 5686 (2022).","journal-title":"IJMS"},{"key":"42471_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou, S., Liu, M., Ren, F., Meng, X. & Yu, J. The landscape of bispecific T cell engager in cancer treatment. Biomark. Res. 9, 38 (2021).","journal-title":"Biomark. Res."},{"key":"42471_CR11","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers15102824","volume":"15","author":"M Shanshal","year":"2023","unstructured":"Shanshal, M., Caimi, P. F., Adjei, A. A. & Ma, W. W. T-Cell Engagers in Solid Cancers\u2014Current Landscape and Future Directions. Cancers (Basel). 15, 2824 (2023).","journal-title":"Cancers (Basel)"},{"key":"42471_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell, J. et al. Bispecific Antibodies in the Treatment of Hematologic Malignancies. Clin. Pharmacol. Ther. 106, 781\u2013791 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"42471_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","volume":"16","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo, A., \u00c1lvarez-Vallina, L. & Sanz, L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J. Hematol. Oncol. 16, 83 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"42471_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2019","unstructured":"Wu, L. et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat. Cancer. 1, 86\u201398 (2019).","journal-title":"Nat. Cancer"},{"key":"42471_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao, Y., Hu, Y. & Wang, F. Trispecific antibodies for cancer immunotherapy. Immunology 169, 389\u2013399 (2023).","journal-title":"Immunology"},{"key":"42471_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/cells8121527","volume":"8","author":"F Morandi","year":"2019","unstructured":"Morandi, F. et al. CD38, a Receptor with Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies. Cells 8, 1527 (2019).","journal-title":"Cells"},{"key":"42471_CR17","first-page":"81","volume":"12","author":"JE Fern\u00e0ndez","year":"1998","unstructured":"Fern\u00e0ndez, J. E. et al. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J. Biol. Regul. Homeost. Agents. 12, 81\u201391 (1998).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"42471_CR18","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/cells9071716","volume":"9","author":"A Kar","year":"2020","unstructured":"Kar, A., Mehrotra, S. & Chatterjee, S. CD38: T Cell Immuno-Metabolic Modulator. Cells 9, 1716 (2020).","journal-title":"Cells"},{"key":"42471_CR19","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/jcp.30760","volume":"237","author":"F Zeng","year":"2022","unstructured":"Zeng, F. et al. Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B\u2010cell\u2010related diseases. J. Cell. Physiol. 237, 2796\u20132807 (2022).","journal-title":"J. Cell. Physiol."},{"key":"42471_CR20","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N Engl. J. Med."},{"key":"42471_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl. J. Med. 373, 1207\u20131219 (2015).","journal-title":"N Engl. J. Med."},{"key":"42471_CR22","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","volume":"118","author":"F Malavasi","year":"2011","unstructured":"Malavasi, F. et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood 118, 3470\u20133478 (2011).","journal-title":"Blood"},{"key":"42471_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cyto.b.20477","volume":"76B","author":"K Mantei","year":"2009","unstructured":"Mantei, K. & Wood, B. L. Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphoma. Cytometry Part. B Clin. 76B, 315\u2013320 (2009).","journal-title":"Cytometry Part. B Clin."},{"key":"42471_CR24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3324\/haematol.2018.211904","volume":"105","author":"A Vidal-Crespo","year":"2020","unstructured":"Vidal-Crespo, A. et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica 105, 1032\u20131041 (2020).","journal-title":"Haematologica"},{"key":"42471_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hon.2904","volume":"39","author":"F Wada","year":"2021","unstructured":"Wada, F. et al. CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. Hematol. Oncol. 39, 483\u2013489 (2021).","journal-title":"Hematol. Oncol."},{"key":"42471_CR26","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","volume":"104","author":"J Naik","year":"2019","unstructured":"Naik, J. et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica 104, e100\u2013e103 (2019).","journal-title":"Haematologica"},{"key":"42471_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","volume":"94","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type. Ann. Hematol. 94, 1381\u20131388 (2015).","journal-title":"Ann. Hematol."},{"key":"42471_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","volume":"14","author":"H Huang","year":"2021","unstructured":"Huang, H. et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J. Hematol. Oncol. 14, 25 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"42471_CR29","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jid.2023.02.011","volume":"143","author":"O Pavlova","year":"2023","unstructured":"Pavlova, O., Tsai, Y. C., Chang, Y. T., Vonow Eisenring, M. & Guenova, E. CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas. J. Invest. Dermatology. 143, 1122\u20131126 (2023).","journal-title":"J. Invest. Dermatology"},{"key":"42471_CR30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jid.2023.01.009","volume":"143","author":"VA Ta","year":"2023","unstructured":"Ta, V. A. et al. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas. J. Invest. Dermatology. 143, 1329\u20131332e3 (2023).","journal-title":"J. Invest. Dermatology"},{"key":"42471_CR31","doi-asserted-by":"crossref","unstructured":"Quaglino, P. et al. CD38 expression by circulating and skin-infiltrating lymphocytes from sezary syndrome patients: A flow cytometry and immunohistochemistry study. Dis. Mark. 1\u20137 (2022).","DOI":"10.1155\/2022\/3424413"},{"key":"42471_CR32","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 Costimulation: From Mechanism to Therapy. Immunity 44, 973\u2013988 (2016).","journal-title":"Immunity"},{"key":"42471_CR33","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.3324\/haematol.2017.186767","volume":"103","author":"D Vallois","year":"2018","unstructured":"Vallois, D. et al. RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica 103, e360\u2013e363 (2018).","journal-title":"Haematologica"},{"key":"42471_CR34","doi-asserted-by":"publisher","first-page":"2015170","DOI":"10.1080\/2162402X.2021.2015170","volume":"11","author":"GJ Lee","year":"2022","unstructured":"Lee, G. J. et al. Mice transgenic for human CTLA4-CD28 fusion gene show proliferation and transformation of ATLL-like and AITL-like T cells. OncoImmunology 11, 2015170 (2022).","journal-title":"OncoImmunology"},{"key":"42471_CR35","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois, D. et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas. Blood 128, 1490\u20131502 (2016).","journal-title":"Blood"},{"key":"42471_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/cas.15191","volume":"113","author":"Y Sakamoto","year":"2022","unstructured":"Sakamoto, Y. et al. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia\/lymphoma. Cancer Sci. 113, 349\u2013361 (2022).","journal-title":"Cancer Sci."},{"key":"42471_CR37","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41375-025-02628-0","volume":"39","author":"G Tari Crochet","year":"2025","unstructured":"Tari Crochet, G. et al. Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model. Leukemia 39, 1744\u20131755 (2025).","journal-title":"Leukemia"},{"key":"42471_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan, K. A., Chini, C. C. S. & Chini, E. N. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front. Immunol. 10, 1187 (2019).","journal-title":"Front. Immunol."},{"key":"42471_CR39","doi-asserted-by":"publisher","first-page":"1146791","DOI":"10.3389\/fimmu.2023.1146791","volume":"14","author":"A Ghosh","year":"2023","unstructured":"Ghosh, A. et al. CD38: an ecto-enzyme with functional diversity in T cells. Front. Immunol. 14, 1146791 (2023).","journal-title":"Front. Immunol."},{"key":"42471_CR40","doi-asserted-by":"publisher","first-page":"e17359","DOI":"10.1371\/journal.pone.0017359","volume":"6","author":"DT Patton","year":"2011","unstructured":"Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R. & Okkenhaug, K. The PI3K p110\u03b4 Regulates Expression of CD38 on Regulatory T Cells. PLoS ONE. 6, e17359 (2011).","journal-title":"PLoS ONE"},{"key":"42471_CR41","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin. Cancer Res. 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"42471_CR42","doi-asserted-by":"crossref","unstructured":"Flores-Borja, F. et al. CD19 + CD24 hi CD38 hi B cells maintain regulatory T cells while limiting T H 1 and T H 17 differentiation. Sci. Transl. Med. 5 (2013).","DOI":"10.1126\/scitranslmed.3005407"},{"key":"42471_CR43","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","volume":"75","author":"TA Karakasheva","year":"2015","unstructured":"Karakasheva, T. A. et al. CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer. Cancer Res. 75, 4074\u20134085 (2015).","journal-title":"Cancer Res."},{"key":"42471_CR44","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38\u2009+\u2009immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"42471_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","volume":"4","author":"AL Keller","year":"2024","unstructured":"Keller, A. L. et al. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies. Cancer Res. Commun. 4, 757\u2013764 (2024).","journal-title":"Cancer Res. Commun."},{"key":"42471_CR46","doi-asserted-by":"crossref","unstructured":"Zabaleta, A. A CD38\/CD3xCD28 Trispecific T-cell engager (TCE) as a potentially active agent in multiple myeloma patients relapsed and\/or refractory (RRMM) to anti-CD38 monoclonal antibodies (mAbs) (2023).","DOI":"10.1182\/blood-2023-182150"},{"key":"42471_CR47","unstructured":"Mart\u00edn-S\u00e1nchez, E. A CD38\/CD3xCD28 T-Cell Engager (TCE) as a potential active agent for the treatment of older patients with Acute Myeloid Leukemia (AML) (2023)."},{"key":"42471_CR48","doi-asserted-by":"publisher","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","volume":"10","author":"NN Bennani","year":"2022","unstructured":"Bennani, N. N. et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J. Immunother Cancer. 10, e004984 (2022).","journal-title":"J. Immunother Cancer"},{"key":"42471_CR49","unstructured":"Gao, Y. et al. Hyperprogression of cutaneous T cell lymphoma after anti\u2013PD-1 treatment. Clin. Med."},{"key":"42471_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jid.2019.07.693","volume":"140","author":"VM Patel","year":"2020","unstructured":"Patel, V. M. et al. Frequent and Persistent PLCG1 Mutations in S\u00e9zary Cells Directly Enhance PLC\u03b31 Activity and Stimulate NF\u03baB, AP-1, and NFAT Signaling. J. Invest. Dermatology. 140, 380\u2013389e4 (2020).","journal-title":"J. Invest. Dermatology"},{"key":"42471_CR51","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41375-025-02551-4","volume":"39","author":"C Isabelle","year":"2025","unstructured":"Isabelle, C. et al. CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention. Leukemia 39, 1146\u20131156 (2025).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42471-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:03:01Z","timestamp":1778425381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42471"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42471-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Kim, K. Bisht, H. Wang, and H. Van de Velde are employees of Sanofi US and A. Dupuy received financial support from Sanofi for a Postdoctoral position. A. Dupuy, N. Ortonne, and P. Gaulard received a research grant from Sanofi US. The other authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14531"}}